Open Access<p>Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy</p>
Author(s) -
Yue Jiang,
Chunzhi Huang,
Yuxia Luan
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s247617
Subject(s) - photothermal therapy , excipient , doxorubicin , drug delivery , doxorubicin hydrochloride , chemistry , nanotechnology , chemotherapy , pharmacology , materials science , medicine , chromatography , surgery
Synergistic treatment integrating photothermal therapy (PTT) and chemotherapy is a promising strategy for hepatocellular carcinoma (HCC). However, the most commonly used photothermal agent, IR820, and chemotherapeutic drug, doxorubicin hydrochloride (DOX), are both hydrophilic molecules that suffer from the drawbacks of a short circulation time, rapid elimination and off-target effects.